Obesity Management

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

By targeting insulin resistance at its source, dual receptor agonists may have a more efficient method of tackling the growing obesity problem, as well as its cardiovascular effects.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

Martin reviews recent trends in cardiovascular disease and contributing underlying risk factors, describing them as a “call to action” for cardiovascular care.

Michos discusses framing obesity as hyperandrogenism, with reductions in estrogen production contributing to higher visceral adiposity.

Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!

Despite the effectiveness of weight loss medications like Ozempic and Wegovy, only 3% of eligible adults receive prescriptions, highlighting significant disparities.

Prevot describes her research exploring the relationship between OSA severity and abdominal obesity metrics as well as changes in both metrics following CPAP.

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.

Discover the latest findings on tirzepatide vs semaglutide for obesity treatment, highlighting significant weight loss results & clinical insights.

New data reveal tirzepatide significantly outperforms semaglutide in weight loss.

Pontecorvi describes the unique features of the EndoZip system and reviews findings from a study on its use for treating obesity-related comorbidities.

The FDA accepted the NDA for oral semaglutide 25 mg, a potentially revolutionary daily treatment for weight management and cardiovascular risk reduction.

In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.

Class 3 obesity conferred the greatest risk of mortality, complications, and higher resource utilization in alcohol-associated hepatitis hospitalizations.

Once-daily orforglipron showed strong efficacy and safety, matching injectable GLP-1s for A1c reduction and weight loss in the ACHIEVE-1 trial.

Patients switching to tirzepatide had greater improvements in HBA1C and weight at week 40 in a phase 4 RCT.